PT-141 (Bremelanotide)
Support sexual health through melanocortin receptor activation.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist derived from Melanotan II. Unlike PDE5 inhibitors that act on the vascular system, PT-141 works through the central nervous system by activating MC3 and MC4 receptors in the hypothalamus, making it effective for both male and female sexual health research.
Key Benefits
- Acts through central nervous system pathways
- Activates melanocortin MC3/MC4 receptors
- Non-vascular mechanism of action
- Studied in both male and female populations
Set a goal (top of the page) to see how PT-141 (Bremelanotide) scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Nausea
- Flushing
- Injection site reactions
- Headache
- Vomiting
- Transient increase in blood pressure
- Focal hyperpigmentation
Legal & Regulatory Status
Prescription required. FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- FDA prescribing information — Vyleesi (bremelanotide), via DailyMed
- RECONNECT: two phase-3 HSDD trials of bremelanotide, Obstet Gynecol (PMID 31599840)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
